Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating

Core Insights - Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is recognized as one of the 10 fastest growing NASDAQ stocks to buy [1] - The company has received positive price target adjustments from Guggenheim and TD Cowen, both raising their targets to $35 while maintaining a Buy rating, reflecting confidence in the company's growth trajectory and product commercialization efforts [2][3] Financial Performance - For Q4 2025, Arcutis reported an EPS of $0.13, exceeding the consensus estimate of $0.09, and Q4 revenue reached $129.5 million, surpassing the consensus of $113.03 million [3] - The company achieved over 90% year-over-year growth in net product revenue in 2025, driven by strong demand for its product ZORYVE and successful execution of multiple product launches [3] Growth Strategy - The CEO, Frank Watanabe, indicated that the company is entering a new growth phase with a solid cash position and resources to invest in the continued growth of ZORYVE and advancement of its pipeline [3]